Overview

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir
Phase:
Phase 2
Details
Lead Sponsor:
The University of Hong Kong
Collaborator:
Hospital Authority, Hong Kong
Treatments:
Interferon beta-1b
Interferon-beta
Interferons
Lopinavir
Ribavirin
Ritonavir